Vildagliptin (CAS 274901-16-5): A Potent DPP-4 Inhibitor for Type 2 Diabetes Management
Explore the therapeutic potential and chemical properties of this key agent in advanced diabetes treatment strategies.
Get a Quote & SampleProduct Core Value
Vildagliptin
Vildagliptin is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically developed as an oral anti-hyperglycemic agent. Its primary mechanism involves enhancing the levels of active incretin hormones, such as GLP-1 and GIP, which in turn improves glycemic control in patients with Type 2 Diabetes Mellitus. Beyond its glucose-lowering effects, Vildagliptin is being investigated for its potential to protect pancreatic beta cells, a critical component in diabetes management.
- Discover the precise mechanism of action for Vildagliptin DPP-4 inhibitors in our detailed analysis. This section delves into how these compounds regulate incretin hormones to manage blood sugar levels effectively.
- Learn about the benefits of using Vildagliptin for type 2 diabetes. We provide insights into its efficacy and potential long-term advantages for patients.
- Explore options to buy Vildagliptin CAS 274901-16-5. Information on sourcing and obtaining this crucial pharmaceutical intermediate is readily available.
- Understand the role of Vildagliptin manufacturers in China. We highlight key suppliers contributing to the global availability of this important API.
Advantages Offered
Improved Glycemic Control
Vildagliptin's mechanism as a DPP-4 inhibitor leads to significant improvements in glycemic control, making it a valuable tool in the fight against Type 2 Diabetes Mellitus.
Potential Beta Cell Protection
Research suggests that Vildagliptin may offer protective effects on pancreatic beta cells, contributing to better long-term diabetes management.
Advanced Pharmaceutical Intermediate
As a key pharmaceutical intermediate, Vildagliptin plays a vital role in the synthesis of advanced antidiabetic drugs, driving innovation in healthcare.
Key Applications
Type 2 Diabetes Treatment
Vildagliptin is a leading oral antihyperglycemic agent used to manage Type 2 Diabetes Mellitus by enhancing incretin hormone activity.
Pharmaceutical Research & Development
Its well-defined properties make Vildagliptin essential for R&D in new antidiabetic drug discovery and optimization.
Chemical Synthesis
As a chemical intermediate, it serves as a crucial building block in the Vildagliptin chemical synthesis pathways for drug manufacturing.
Glycemic Control Strategies
Vildagliptin is central to developing effective glycemic control strategies, offering a novel approach to diabetes therapy.